Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Dow
Queensland Health
Fish and Richardson
Johnson and Johnson
Federal Trade Commission
Cipla
Daiichi Sankyo
Colorcon

Generated: October 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,758,891

« Back to Dashboard

Which drugs does patent 7,758,891 protect, and when does it expire?

Patent 7,758,891 protects ABRAXANE and is included in one NDA.

This patent has eighty-five patent family members in twenty-five countries.

Summary for Patent: 7,758,891
Title:Combinations and modes of administration of therapeutic agents and combination therapy
Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Inventor(s): Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA)
Assignee: Abraxis Bioscience, LLC (Los Angeles, CA)
Application Number:12/334,115
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,758,891

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF PANCREATIC CANCER ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,758,891

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 531365 ➤ Try a Free Trial
Australia 2006213999 ➤ Try a Free Trial
Australia 2007317859 ➤ Try a Free Trial
Brazil PI0607809 ➤ Try a Free Trial
Brazil PI0718528 ➤ Try a Free Trial
Canada 2598239 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Covington
Colorcon
Accenture
Cantor Fitzgerald
QuintilesIMS
Chubb
Federal Trade Commission
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.